- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05325229
A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer
A Single-arm, Multicenter, Phase II Clinical Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will be conducted in two stages (dose escalation trial and phase II trial). Dose escalation trial: To explore the safety and tolerability of Docetaxel for Injection (Albumin-bound) (75 mg/m^2 and 100 mg/m^2) combined with Bevacizumab 15 mg/kg. Dose escalation will be started at low dose and proceed in turn.
Phase II trial: According to the recommended phase II dose (RP2D) determined in the dose escalation trial, a phase II study of Docetaxel for Injection (Albumin-bound) combined with Bevacizumab will be conducted to observe the efficacy of the combination regimen, with overall response rate (ORR) as the primary study endpoint. Simon's optimal 2-stage design will be adopted for phase II study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Zhe Zhang
- Phone Number: 1315039707
- Email: zhangzhe@mail.ecspc.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China
- Recruiting
- Tongji hospital,Tongji Medical college of HUST
-
Contact:
- Ding Ma
- Phone Number: +86-13886090620
- Email: dingma424@126.com
-
Contact:
- Qinglei Gao
- Phone Number: +86-13871127473
- Email: 2482880446@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged ≥18, ≤78 years (subject to the date when the informed consent form is signed) and voluntarily signed the informed consent form.
- Histologically or cytologically confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Patients who responded to their last line of platinum treatment, and the disease recurred or progressed between 28 days to 6 months (184 calendar days) after the last platinum therapy (platinum-resistant disease), with no more than two lines of non-platinum therapy.
- At least one measurable lesion according to RECIST v1.1.
- Patients with Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
- Patients with estimated survival time of ≥ 3 months.
Main organ function meets the following criteria within 7 days before treatment (no medical supportive treatments such as blood component transfusion, human granulocyte colony-stimulating factor (G-CSF), thrombopoietin (TPO), interleukin-11, and erythropoietin (EPO) within 2 weeks before administration of the investigational drug):
Absolute neutrophil count ≥1.5×10^9/L; Platelets ≥100×10^9/L; Hemoglobin ≥90 g/L or ≥5.6 mmol/L; Serum creatinine ≤ 1.5×ULN or creatinine clearance rate ≥ 40 mL/min; Liver function: total bilirubin≤ 1.0 × ULN, ≤ 1.5 × ULN for patients with liver metastasis; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 × ULN, ≤ 2.5 × ULN for patients with liver metastasis.
Activated Partial Thromboplastin Time (APTT) ≤ 1.5×ULN, International Normalized Ratio (INR) ≤ 1.5×ULN.
- The patient must agree to take adequate contraception from signing of ICF through 6 months after last dose, women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to the first dose of the investigational drug.
Exclusion Criteria:
- Patients who have received anti-angiogenic therapy (including but not limited to bevacizumab, apatinib, anlotinib, etc.) within 18 weeks before the first use of the investigational drug.
- The progression-free interval of previous docetaxel treatment was less than 6 months.
- Patients whose disease progressed during platinum therapy (from the first dose to 28 days after the last dose).
- Mucinous ovarian cancer or less malignant ovarian tumors (such as low-grade serous ovarian cancer).
- Symptomatic central nervous system (CNS) metastases or cancerous meningitis (Patients may participate in this study if they have completed radiotherapy or surgery for CNS metastases prior to screening, and the patient's nervous system has been stable for ≥4 weeks after radiotherapy or post-surgery (i.e., no new neurological deficits due to brain metastases, no new lesions on CNS imaging, and no treatment is required at screening)).
- History of other malignant tumors within 5 years before the first dose of the investigational drug, except for the following: curable cancer such as basal cell or squamous cell skin cancer, superficial bladder cancer, prostate cancer, cervical cancer or breast cancer in situ that had been cured.
- Patients with a history of thromboembolism, cerebral infarction, hemorrhagic disease or bleeding tendency within 6 months before the first dose of the investigational drug.
- History of intestinal obstruction, gastrointestinal perforation, abdominal fistula or abdominal abscess within 6 months before the first dose of the investigational drug.
- Abdominal or pelvic radiotherapy within 5 years before the first dose of the investigational drug.
- Urine protein >2+, or urine protein is 2+ with 24-hour urine protein quantitative >1g at screening.
- Patients who are known to be allergic to the investigational drug or its main excipients.
- Patients with an uncontrollable third space effusion (e.g. pleural effusion, ascites, or pericardial effusion), who, in the judgment of the investigator, are not suitable for the study.
Patients with a history of severe cardiovascular disease, including but not limited to:
- Severe heart rhythm or conduction abnormalities, including but not limited to ventricular arrhythmia requiring clinical intervention and third degree atrioventricular block within 6 months before the first dose of the investigational drug;
- History of myocardial infarction, angina pectoris, angioplasty and coronary artery bypass surgery within 6 months before the first dose of the investigational drug;
- Heart failure with New York Heart Association (NYHA) Classification of Class III and above;
- Poorly controlled hypertension (Systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 95 mmHg at screening period despite optimal therapy);
- Patients with prolonged QT/QTc interval (QTcF > 480 ms, Fridericia's formula: QTcF = QT/RR^0.33, RR = 60/heart rate) during the screening period;
- Left ventricular ejection fraction (LVEF) <50% during the screening period.
- HCV antibody (+) is positive during the screening period (HCV RNA negative can be included, anti-HCV treatment other than interferon is allowed), active hepatitis B disease (HBV DNA ≤2000 IU/mL can be included, anti-HBV treatment other than interferon is allowed), HIV positive, or with acquired immunodeficiency syndrome (AIDS).
- Patients who have undergone major organ surgery within 4 weeks before the first dose of the investigational drug, or who need to undergo elective surgery during the study.
- Adverse reactions from the previous anti-tumor treatment have not yet recovered to ≤ level 1 based on CTCAE 5.0 (except for the toxicity without safety risk judged by the investigator, such as Grade 2 neuropathy, alopecia).
- Patients who have received anti-tumor treatments such as chemotherapy, targeted therapy, immunotherapy and other clinical study drugs within 4 weeks before the first dose of the investigational drug, and other conditions are as follows: Local palliative radiotherapy within 2 weeks before the first dose of the investigational drug; oral fluoropyrimidines, small molecule targeted drugs, etc. within 2 weeks before the first dose of the investigational drug or within known 5 half-lives of the drug (whichever is longer); Traditional Chinese medicines with anti-tumor indications within 2 weeks before the first dose of the investigational drug.
- Patients who have used potent inhibitors or inducers of CYP3A4 within 2 weeks before the first dose of the investigational drug.
- Patients who have received a live attenuated vaccine within 4 weeks before the first use of the investigational drug.
- Patients who have taken aspirin (>325mg/day) or other non-steroidal anti-inflammatory drugs that may affect platelet function within 10 days before the first use of the investigational drug.
- Nursing women.
- Patients with active infection requiring intravenous antibiotic therapy (at the discretion of the investigator).
- Patients with a history of alcohol or drug dependence.
- Other situations that the investigator considers not suitable for participating in the clinical study, including but not limited to: the patient is complicated by severe or uncontrolled medical conditions, which interfere with the interpretation of study results and affect the study compliance.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Docetaxel combined with Bevacizumab
Docetaxel for Injection (Albumin-bound) will be administrated once every 3 weeks at a dose of 75 mg/m^2 or 100 mg/m^2; Bevacizumab will be administrated once every 3 weeks at a dose of 15mg/kg.
|
Docetaxel for injection (Albumin-bound), by intravenous infusion,75 mg/m^2 or 100 mg/m^2 once every 3 weeks.
Bevacizumab, by intravenous infusion, 15 mg/kg once every 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dose escalation trial: Incidence of adverse event(AE)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Phase II trial: Overall response rate (ORR) by Independent Review Committee(IRC)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Dose escalation trial: Serious adverse event(SAE )
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Dose escalation trial: Dose limiting toxicity(DLT).
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose escalation trial and Phase II trial: Plasma concentration of docetaxel (free and total
Time Frame: Up to approximately 3 months
|
Up to approximately 3 months
|
|
Phase II trial: ORR by investigator
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Phase II trial: Disease control rate (DCR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Phase II trial: Duration of Response (DOR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Phase II trial: Progression-Free-Survival (PFS)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Phase II trial: Overall survival (OS)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Phase II trial: CA125 response rate
Time Frame: Up to approximately 2 years
|
Proportion of patients with a minimum 50% reduction in CA125 serum levels lasting for 28 days relative to baseline CA-125 serum levels, for patients whose baseline CA-125 serum levels ≥2×ULN.
|
Up to approximately 2 years
|
Phase II trial: Incidence of AE
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Phase II trial: abnormal vital signs
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Phase II trial: abnormal physical examination
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Phase II trial: abnormal electrocardiogram
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Phase II trial: abnormal laboratory tests
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Phase II trial: Eastern Cooperative Oncology Group(ECOG) scores
Time Frame: Up to approximately 2 years
|
There are 6 values (0, 1,2,3,4,5) in the ECOG score system.
A higher score means a worse outcome, for example, 0 means normal, 5 means death.
|
Up to approximately 2 years
|
Collaborators and Investigators
Investigators
- Study Director: Xuekun Yao, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Docetaxel
- Bevacizumab
Other Study ID Numbers
- HB1801-005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Platinum-resistant Recurrent Ovarian Cancer
-
M.D. Anderson Cancer CenterActive, not recruitingRecurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary Peritoneal Carcinoma | Recurrent Primary Peritoneal...United States
-
Aduro Biotech, Inc.Incyte CorporationTerminatedPlatinum-resistant Ovarian Cancer | Platinum-resistant Fallopian Cancer | Platinum-resistant Peritoneal CancerUnited States, Canada
-
Roswell Park Cancer InstituteActive, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Refractory Ovarian... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyWithdrawnRecurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary... and other conditionsUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Peritoneal Carcinomatosis | Malignant Peritoneal Neoplasm | Recurrent Endometrial Carcinoma | Stage IVB Uterine Corpus Cancer AJCC v8 | Recurrent Cervical Carcinoma | Metastatic Malignant Female... and other conditionsUnited States
-
Seoul National University HospitalPharos iBio Co., Ltd.RecruitingPlatinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-refractory Ovarian CarcinomaKorea, Republic of
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Not yet recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary Peritoneal CarcinomaUnited States
Clinical Trials on Docetaxel for injection (Albumin-bound)
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingPancreatic CancerChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Active, not recruitingAdvanced Solid TumorsChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruiting
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingGastric Adenocarcinoma | Adenocarcinoma of Gastroesophageal JunctionChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingLocally Advanced Unresectable Esophageal Squamous CarcinomaChina
-
China Medical University, ChinaRecruiting
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.UnknownNon-Small Cell Lung CancerChina
-
Sun Yat-sen UniversityShanghai Junshi Bioscience Co., Ltd.; CSPC Ouyi Pharmaceutical Co., Ltd.RecruitingEsophageal Small Cell CarcinomaChina
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdNot yet recruiting
-
Peking UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingGastric Cancer | Adenocarcinoma of Esophagogastric JunctionChina